Pfizer plans to request authorization for its coronavirus vaccine for children aged 2-11 by September. The company also expects to hear back from the FDA “shortly” on whether its vaccine will be authorized for 12-15-year-olds.
Extra: The announcements were made during the company’s Q1 earnings call, during which it noted that the coronavirus vaccine accounted for $3.5B (24% of Q1 revenue).
The New Paper
This story is from the May 5, 2021 edition of The New Paper. To receive TNP daily subscribe below.
By subscribing, you agree to our Terms of Service & Privacy Policy.
